The Centers for Disease Control and Prevention says that a formulation of Endo's pain med, Opana ER--that's supposed to be difficult to crush--is responsible for an outbreak of HIV in southern Indiana, because the changes made it easier to prepare the drug for more dangerous intravenous or subcutaneous injection.
Endo hasn't quite wrapped up its $8 billion deal for generics maker Par Pharmaceutical, recently agreeing to a loan package to speed things along. Now, the drugmaker is hoping to move one step closer to the finish line by launching a $1.75 billion stock sale.
Earlier this week, Endo inked a pact to nab Par Pharmaceutical for $8 billion. But to do that, it'll need a loan, and it's agreed to a $9.275 billion loan package to back the acquisition.
Endo is acquiring Par Pharmaceutical for $8 billion. It adds about 100 products from Par, such as generic injectables worth $1.3 billion in 2014 sales.
Endo Pharmaceuticals and BioDelivery Sciences International announced positive results from two Phase III studies of their Belbuca buccal film to manage severe chronic pain by quickly delivering buprenorphine via the inside of the cheek. The candidate uses BDSI's BioErodible MucoAdhesive delivery platform.
After Endo lost Salix earlier this year, analysts didn't think there would be much left for the drugmaker in terms of M&A. But now, the company is snatching up generics maker Par Pharmaceutical for $8 billion, getting its hands on the company's generic drug portfolio to expand its offerings and generate long-term growth.
Not satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus. Endo is doubling the size of the Stendra salesforce, rolling out a new DTC effort, and keeping a close eye on inventory levels, which had built up too much for its taste.
Upon buying up Auxilium--which markets Vivus' erectile dysfunction drug Stendra--Endo decided wholesale inventory levels weren't where they ought to be. Its solution? A relaunch of the drug, complete with a new salesforce and DTC efforts.
Boston Scientific is looking determinedly toward the future with a new partnership with deep brain stimulation player Brainlab and positive data for its peripheral artery disease drug-eluting stent. But the past keeps weighing upon it as litigation costs pile up from vaginal mesh lawsuits and the recent settlement with Johnson & Johnson over the long-standing Guidant dispute.
As Endo showed last week with its failed $10 billion bid for North Carolina's Salix, it's willing to shell out some serious dough if the right target comes along. The question is, what's left?